SUMMARY Of the 123 patients with acute mesenteric infarction treated over the past 12 years, 16 (13%) had mesenteric venous thrombosis. Eight of the patients with mesenteric venous thrombosis survived the initial episode; two have since died. The remaining six patients were studied for evidence of haemostatic deficiencies or abnormalities. Antithrombin III deficiency, which is known to be associated with recurrent venous thrombosis, was found in three patients. It is recommended that all patients with mesenteric venous thrombosis should be screened for antithrombin III 26 March 1987 thrombosis secondary to acute necrotising pancreatitis. In the remaining patients no recognised underlying cause of thrombosis could be implicated although one developed mesenteric venous thrombosis three weeks after giving birth and another had evidence of secondary polycythaemia on admission; both factors were likely to have been of importance. Thrombosis was not associated with use of oral contraceptives. Three patients (19%) had a history of thrombotic episodes, one had had mesenteric venous thrombosis nine years before and the other two each had had an episode of deep vein thrombosis.
Eight patients (50%) survived the initial episode, and two of them have since died. The remaining six patients were studied for evidence of haemostatic deficiencies or abnormalities.
ATIII and plasminogen antigen were measured by radial immunodiffusion ( 
Discussion
Antrithrombin III is the most important naturally occurring antithrombin. It inhibits thrombin and also factor Xa, and thus regulates thrombin formation. ATIII is an a-2-globulin with a molecular weight of around 65 000. It is synthesised in the liver and has a narrow physiological range in plasma, values below this range being associated with an increased tendency to venous thrombosis. Deficiency ofATIII may result from impaired or faulty synthesis in congenital or acquired disorders, increased consumption or catabolism, loss from the intravascular compartment, or from unknown causes.9
Hereditary ATIII deficiency is usually transmitted as an autosomal dominant and such families have a high incidence of venous thrombosis. Over 85% of those aged 50 or older have had at least one thrombotic episode, often precipitated by pregnancy, parturition, surgery, trauma, or use of oral contraceptives.9 The mesenteric veins are a rare but characteristic site of thrombosis in familial ATIII 907 908
Wilson, Walker, Davidson, Imrie deficiency, affecting 8% of reported cases. 10 Biochemical and haematological evidence suggested liver dysfunction as a possible cause for ATIII deficiency in case 2. ATIII concentrations may be reduced in chronic liver disease, but because of a simultaneous decrease in the procoagulants, there may be no increased risk of thrombosis.9 In case 2, despite the reduced procoagulants, the ATIII deficiency and thrombocythaemia presumably favoured thrombosis.
The aetiology of ATIII deficiency in the two other patients remains unclear, although in case 1 there may have been a liver abnormality. We were unable to show the deficiency in the other family members who were available for testing. Patients did not have abnormal plasminogen values and none had protein C deficiency, although this is thought to be commoner than ATIII deficiency.`1 Moderate ATIII deficiency seems to have been a factor in three of the six survivors from mesenteric venous thrombosis tested, and it may explain the mechanism of thrombosis in some patients who would previously have been classified as having primary mesenteric venous thrombosis. Familial ATIII deficiency is a recognised but rare cause of mesenteric venous thrombosis. Our study suggests that even acquired ATIII deficiency may be associated with this condition, and we would therefore recommend investigating all patients with mesenteric venous thrombosis for ATIII deficiency as soon as the condition is suspected. In the presence of clinically important thrombosis ATIII activity may be decreased due to ATIII consumption and therefore results in the acute phase of the illness should be interpreted with caution. ATIII activity may fall further in the postoperative period if the patient remains unwell due to infection, septicaemia, or disseminated intravascular coagulation.9 Careful follow up with repeated ATIII estimation is therefore essential to avoid mislabelling patients whose ATIII activity subsequently returns to normal. Families of those discovered to have ATIII deficiency should also be studied to exclude familial deficiency because of their very high risk of thrombotic disease.
Treatment with coumarin anticoagulants provides effective prophylaxis further thrombosis in ATIII deficiency12 and is indicated in familial cases, in those with a low ATIII activity associated with previous thrombotic episodes, and particularly in situations likely to predispose to thrombosis such as surgery. In pregnancy, due to the teratogenic risks associated with coumarin anticoagulants, prophylactic anticoagulation with heparin is preferable at least during the first trimester.'0 Immediately after surgery anticoagulation with heparin alone may be ineffective in preventing further thrombosis in patients with ATIII deficiency. The concurrent administration of ATIII concentrate and heparin permits immediate, full anticoagulation, although the doses of both require careful laboratory monitoring,12 which for ATIII, should be by a functional amidolytic assay. '3 We thank Dr J Conkie and the staff of the Thrombosis Research Laboratory for performing the assays.
